

***Fiscal Year 2022 Traumatic Brain Injury and Psychological Health Research Program (TBIPHRP)  
Reference Table of Award Mechanisms and Submission Requirements***

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p><b>Clinical Trial Award (CTA)</b></p> <p><b>Go to:</b></p> <ul style="list-style-type: none"> <li>• <a href="#">Targeted Broad Agency Announcement</a></li> <li>• <a href="#">General Submission Instructions</a></li> </ul> <p><b>Grants.gov Funding Opportunity Number:</b></p> <p><a href="#">W81XWH-22-S-TBIPH1</a></p>	<p>Extramural applicants only</p> <p>Investigators at the level of Assistant Professor and above (or equivalent)</p> <p>Early-Career Investigator Partnering Option: An independent, early-career investigator within 10 years after completion of terminal degree by the time of the application submission deadline (excluding time spent in residency or on family medical leave).</p>	<ul style="list-style-type: none"> <li>• Supports the rapid implementation of clinical trials with the potential to have a significant impact on psychological health and/or TBI through clinical applications, including healthcare products, technologies, and/or practice guidelines.</li> <li>• <b>Submissions of preproposal is required; application submission is by invitation only.</b></li> <li>• Different Research Levels, based on the scope of research, are available. It is the responsibility of the Principal Investigator (PI) to select the Research Level that is most appropriate for the research proposed.</li> </ul> <p><i>The following are general descriptions, although not all-inclusive, of the scope of the research projects that would be appropriate to propose under each Research Level:</i></p> <ul style="list-style-type: none"> <li>• <b>Research Level 1:</b> Proof-of-principle pilot trials, correlative studies, and other innovative, exploratory clinical trials. <ul style="list-style-type: none"> <li>○ Early-Career Partnering Investigator Option is available</li> </ul> </li> <li>• <b>Research Level 2:</b> Clinical trials for promising treatments or interventions that have already demonstrated acceptable safety in human subjects.</li> <li>• <b>Research Level 3:</b> Large-scale clinical trials to demonstrate efficacy in relevant patient populations.</li> </ul>	<p><b><u>Research Level 1</u></b></p> <ul style="list-style-type: none"> <li>• Maximum funding of <b>\$500,000</b> for direct costs (plus indirect costs)</li> <li>• Maximum period of performance is <b>3</b> years</li> </ul> <p><b><u>Research Level 2</u></b></p> <ul style="list-style-type: none"> <li>• Maximum funding of <b>\$2,000,000</b> for direct costs (plus indirect costs)</li> <li>• Maximum period of performance is <b>4</b> years</li> </ul> <p><b><u>Research Level 3</u></b></p> <ul style="list-style-type: none"> <li>• Maximum funding of <b>\$4,000,000</b> for direct costs (plus indirect costs)</li> <li>• Maximum period of performance is <b>4</b> years</li> </ul>	<p><b>Pre-Application (Preproposal):</b> September 1, 2022 5:00 p.m. Eastern time</p> <p><b>Application:</b> December 8, 2022 11:59 p.m. Eastern time</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p><b>Focused Program Award (FPA)</b></p> <p><b>Go to:</b></p> <ul style="list-style-type: none"> <li>• <a href="#">Targeted Broad Agency Announcement</a></li> <li>• <a href="#">General Submission Instructions</a></li> </ul> <p><b>Grants.gov Funding Opportunity Number:</b></p> <p><a href="#">W81XWH-22-S-TBIPH2</a></p>	<p>Extramural applicants only</p> <p>Investigators at the level of Assistant Professor and above (or equivalent)</p>	<ul style="list-style-type: none"> <li>• Supports a synergistic, multidisciplinary research program of at least four distinct but complimentary projects addressing an overarching goal.</li> <li>• Individual projects must be capable of standing on their own high scientific merits, they must also be interrelated, synergistic, and align with the overarching challenge to advance a solution beyond what would be possible through individual efforts.</li> <li>• Individual research projects may include applied research, preclinical research, clinical research and clinical trials. Proposed research projects should not include basic research. Research team of highly qualified, multidisciplinary project leaders should be led by a PI with demonstrated success in directing large, focused projects.</li> <li>• <b>Submission of a preproposal is required; application submission is by invitation only.</b></li> </ul>	<ul style="list-style-type: none"> <li>• Maximum funding of <b>\$5,000,000</b> for direct costs (plus indirect costs)</li> </ul> <p>Maximum period of performance is <b>4</b> years</p>	<p><b>Pre-Application (Preproposal):</b> September 1, 2022 5:00 p.m. Eastern time</p> <p><b>Application:</b> December 8, 2022 11:59 p.m. Eastern time</p>
<p><b>Investigator Initiated Research Award (IIRA)</b></p> <p><b>Go to:</b></p> <ul style="list-style-type: none"> <li>• <a href="#">Program Announcement</a></li> <li>• <a href="#">General Application Instructions</a></li> </ul> <p><b>Grants.gov Funding Opportunity Number:</b></p> <p><a href="#">W81XWH-22-TBIPHRP-IIRA</a></p>	<p>Investigators at the level of Assistant Professor and above (or equivalent)</p> <p>Early-Career Investigator Partnering Option: An independent, early-career investigator within 10 years after completion of terminal degree by the time of the application submission deadline (excluding time</p>	<ul style="list-style-type: none"> <li>• Supports research that will make an important contribution toward understanding, preventing, assessing, and treating psychological health and/or TBI conditions.</li> <li>• Early-Career Partnering PI Option is available.</li> <li>• Clinical trials will not be supported.</li> <li>• <b>Submission of a Letter of Intent is required prior to full application submission.</b></li> </ul>	<ul style="list-style-type: none"> <li>• Maximum funding of <b>\$500,000</b> for direct costs (plus indirect costs)</li> <li>• Maximum period of performance is <b>3</b> years</li> </ul>	<p><b>Pre-Application (Letter of Intent):</b> August 24, 2022 5:00 p.m. Eastern time</p> <p><b>Application:</b> September 14, 2022 11:59 p.m. Eastern time</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
	spent in residency or on family medical leave).			
<p><b>Translational Research Award (TRA)</b></p> <p><b>Go to:</b></p> <ul style="list-style-type: none"> <li><a href="#">Program Announcement</a></li> <li><a href="#">General Application Instructions</a></li> </ul> <p><b>Grants.gov Funding Opportunity Number:</b></p> <p><a href="#">W81XWH-22-TBIPHRP-TRA</a></p>	Investigators at the level of Assistant Professor and above (or equivalent)	<ul style="list-style-type: none"> <li>Supports the translation of promising research into clinical application (i.e., preclinical to clinical translation).</li> <li>May support small-scale pilot clinical trial when necessary to inform the next step in clinical development</li> <li>Partnering PI Option is available.</li> <li><b>Submission of a Letter of Intent is required prior to full application submission.</b></li> </ul>	<ul style="list-style-type: none"> <li>Maximum funding of <b>\$1,000,000</b> for direct costs (plus indirect costs)</li> <li>Maximum period of performance is <b>3</b> years</li> </ul>	<p><b>Pre-Application (Letter of Intent):</b> August 24, 2022 5:00 p.m. Eastern time</p> <p><b>Application:</b> September 14, 2022 11:59 p.m. Eastern time</p>
<p><b>Patient-Centered Research Award (PCRA)</b></p> <p><b>Go to:</b></p> <ul style="list-style-type: none"> <li><a href="#">Program Announcement</a></li> <li><a href="#">General Application Instructions</a></li> </ul> <p><b>Grants.gov Funding Opportunity Number:</b></p> <p><a href="#">W81XWH-22-TBIPHRP-PCRA</a></p>	Investigators at the level of Assistant Professor and above (or equivalent)	<ul style="list-style-type: none"> <li>Supports research to bridge the gap between research, practice, and policy by building a knowledge base on how interventions and clinical practices/guidelines and policies can be deployed to targeted populations at the appropriate time at the point of need.</li> <li>Funding from this award mechanism must support clinical research or clinical trials but cannot be used for preclinical or animal research.</li> <li>The application <b>must</b> include Community-Based Participatory Research (CBPR) approaches in the development and execution of the clinical research/trial. .</li> <li>FY22 PCRA may support (not all inclusive):</li> <li>Comparative effectiveness research comparing the benefits and harms of emerging or established interventions and strategies to prevent, diagnose, treat and monitor health conditions in “real world” settings.</li> <li>Development and evaluation of strategies to overcome barriers to the adoption, adaptation, integration, scale-up and sustainability of evidence-based interventions, tools, policies, and guidelines.</li> </ul>	<ul style="list-style-type: none"> <li>Maximum funding of <b>\$1,000,000</b> for direct costs (plus indirect costs)</li> <li>Maximum period of performance is <b>3</b> years</li> </ul>	<p><b>Pre-Application (Letter of Intent):</b> August 24, 2022 5:00 p.m. Eastern time</p> <p><b>Application:</b> September 14, 2022 11:59 p.m. Eastern time</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
		<ul style="list-style-type: none"> <li>• Analysis of existing data or resources to inform clinical practice</li> <li>• Modification of established clinical tools for their intended population or environment</li> <li>• Analysis of existing clinical tools to maximize patient-relevant outcomes</li> <li>• Identification and analysis of the circumstances that create a need to stop or reduce (“de-implement”) the use of interventions, tools, policies, and guidelines that are ineffective, unproven, low-value, or harmful is within scope.</li> <li>• <b>Submission of a Letter of Intent is required prior to full application submission.</b></li> </ul>		